•
GO
GOVX
GeoVax Labs, Inc. New
polygonPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
5.16M
Volume
244.48K
52W High
$56.00
52W Low
$2.61
Open
$3.03
Prev Close
$2.98
Day Range
2.95 - 3.42
About GeoVax Labs, Inc. New
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
Latest News
Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities
Benzinga•Jul 16
Presenting on Emerging Growth Conference 84 Day 2 on July 17; Register to live stream
GlobeNewswire Inc.•Jul 16
Presenting on the Emerging Growth Conference 78 Day 2 on January 16 Register Now
GlobeNewswire Inc.•Jan 15
GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference
GlobeNewswire Inc.•Nov 26
GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire Inc.•Nov 12
GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024
GlobeNewswire Inc.•Nov 5
GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
GlobeNewswire Inc.•Oct 2
GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market
GlobeNewswire Inc.•Aug 29